Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC -- Ignore unavailable to you. Want to Upgrade?

To: Shlepper who wrote (1859)	6/19/1999 11:03:00 AM
From: gEc	Read Replies (2) \| Respond to of 2028

"Since I'm invested (mostly small) in around 100 companies,.." It seems that you manage your own mutual fund. How do keep track of them all? If you don't mind my asking, have you been doing better than the market, or equivalently structured mutual funds? I think that carrying such a large portfolio is a good strategy - but it must take a lot of effort. Any other pharmaceuticals or biotechs? gEc

To: Shlepper who wrote (1859)	6/19/1999 11:54:00 AM
From: Jim Oravetz	Respond to of 2028

I would have to mostly agree with your general assessment of the insider activity (buys or sells). Certainly, if BTGC was at $15/sh, less people would be complaining about the sales. Sims has been with the company a long time and overall, has produced positive results -- they were one of only a handful of biotech that were actually making money when I bought in in '96 or so. IMHO, the selling now sends a message that the people who have access to the sales numbers are not too optimistic that sales will pick up in the next few quarters. Oslten said the pipeline is filled. I could be wrong and the numbers of prescriptions will actually increase significantly. My guess is that they will not. Additionally, the sales from the Jap. Co.'s (hGH) are not quite ready to contribute substantially to profits. Sims stated that the Hep-B drug, while an additional rev. source, will NOT be that significant a profit center since it competes with drugs that cost $1-2 dollars. The testosterone drug is still kind of stuck in short term limbo. OxSOD is by all intents, on hold. The ophthalmic sol'n sales should start to expand. BTGC does not have a $100M+ drug in its portfolio and therefor it is shunned by many funds. Short term (2-3qtrs), the stock will suffer and I still think it will retract to the $5+ trading range. Long term, BTGC is looking for more drugs to (co-)develop and or purchase. The results for the just announced cancer stuff is 5-6 yrs away, IF IT WORKS AT ALL. They really need something with some legs to carry the stock forward and take advantage of the money they are spending to develop expanded mnfg in Israel. OT ++ from your profile, looks like QCOM is money in the bank for you. Congrat's Jim